No information is available on the clinical use of bortezomib during breastfeeding. Because bortezomib is 83% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of up to 193 hours, the manufacturer recommends that breastfeeding be discontinued during bortezomib therapy and for 2 months after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Bortezomib
CAS Registry Number
179324-69-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Proteasome Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
